Physician profile
Felix Thomas
NPI 1427412949
$3,125.69
in general payments reported to CMS, 2019-2025
24 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $348 · 2021: $662 · 2022: $473 · 2023: $680 · 2024: $261 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $529.93 | 2019-2023 | Coroflow |
| Amgen INC. | $517.99 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $405.75 | 2022-2025 | |
| Boston Scientific Corporation | $389.44 | 2019-2023 | Rigiflex II |
| E.R. Squibb & Sons, L.L.C. | $209.15 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $185.09 | 2021-2023 | Corevalve Evolut R, Harmony |
| Impulse Dynamics (USA) INC. | $146.99 | 2022-2023 | Optimizer |
| Pfizer INC. | $105.62 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.40 | 2022-2023 | Farxiga |
| Heartflow, INC. | $60.72 | 2023 | Ffrct |
| Lantheus Medical Imaging, INC. | $49.85 | 2019-2020 | |
| Cvrx, INC. | $49.65 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $48.55 | 2023 | Xarelto |
| Irhythm Technologies, INC. | $44.76 | 2022-2023 | Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $44.71 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $44.40 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $44.32 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.11 | 2021-2023 | Jardiance |
| Chiesi USA, INC. | $31.23 | 2021 | |
| Exact Sciences Corporation | $30.46 | 2024 | Cologuard Collection Kit |
| Medtronic Vascular, INC. | $27.69 | 2020 | |
| Novo Nordisk INC | $21.75 | 2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $19.96 | 2019 | |
| Recor Medical INC | $18.17 | 2024 | Paradise Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.